A detailed history of Bank Of Nova Scotia transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of Nova Scotia holds 6,634 shares of ALNY stock, worth $1.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,634
Previous 13,363 50.36%
Holding current value
$1.82 Million
Previous $2 Million 19.28%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$143.31 - $247.0 $964,332 - $1.66 Million
-6,729 Reduced 50.36%
6,634 $1.61 Million
Q1 2024

May 14, 2024

BUY
$146.51 - $198.2 $1.08 Million - $1.45 Million
7,338 Added 121.79%
13,363 $2 Million
Q4 2023

Feb 12, 2024

BUY
$151.41 - $196.57 $465,888 - $604,845
3,077 Added 104.38%
6,025 $1.15 Million
Q3 2023

Nov 14, 2023

BUY
$170.77 - $211.65 $78,041 - $96,724
457 Added 18.35%
2,948 $522,000
Q2 2023

Aug 03, 2023

SELL
$185.01 - $212.05 $140,607 - $161,158
-760 Reduced 23.38%
2,491 $473,000
Q1 2023

May 11, 2023

SELL
$182.66 - $235.53 $211,885 - $273,214
-1,160 Reduced 26.3%
3,251 $651,000
Q4 2022

Feb 09, 2023

BUY
$185.53 - $241.31 $186,272 - $242,275
1,004 Added 29.47%
4,411 $1.05 Million
Q3 2022

Nov 10, 2022

BUY
$138.54 - $232.0 $112,633 - $188,616
813 Added 31.34%
3,407 $682,000
Q2 2022

Aug 08, 2022

BUY
$120.42 - $169.29 $312,369 - $439,138
2,594 New
2,594 $378,000
Q2 2022

Aug 05, 2022

SELL
$120.42 - $169.29 $862,568 - $1.21 Million
-7,163 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$127.18 - $173.91 $724,798 - $991,113
5,699 Added 389.28%
7,163 $1.17 Million
Q4 2021

Feb 11, 2022

BUY
$159.56 - $209.29 $233,595 - $306,400
1,464 New
1,464 $249,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $33.8B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Bank Of Nova Scotia Portfolio

Follow Bank Of Nova Scotia and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Nova Scotia, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Nova Scotia with notifications on news.